Point72 Asset Management’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.5M Buy
+473,308
New +$15.3M 0.02% 935
2026
Q1
Sell
-313,492
Closed -$10.1M 4556
2025
Q4
$11M Buy
+313,492
New +$11.1M 0.01% 1296
2025
Q3
Sell
-39,930
Closed -$1.06M 2707
2025
Q2
$1.06M Buy
+39,930
New +$1.05M ﹤0.01% 1536
2024
Q2
Sell
-133,990
Closed -$11M 2492
2024
Q1
$11M Buy
+133,990
New +$5.96M 0.03% 683
2023
Q3
Sell
-303,957
Closed -$4.93M 2906
2023
Q2
$4.93M Sell
303,957
-789,378
-72% -$16.5M 0.01% 819
2023
Q1
$18.2M Sell
1,093,335
-12,265
-1% -$127K 0.06% 382
2022
Q4
$10.4M Buy
+1,105,600
New +$4.94M 0.04% 537

Other funds holding VKTX

Point72 Asset Management's VKTX Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 473,308 shares worth $18.5M. The stake represents 0.02% of the portfolio and ranks #935 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in VKTX as recently as Q4 2025.

Point72 Asset Management first reported a position in VKTX in Q4 2022 and has held it in 7 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Point72 Asset Management held 473,308 shares of Viking Therapeutics worth $18.5M as of Q2 2026.
  • Viking Therapeutics was a new Point72 Asset Management position in Q2 2026.
  • Viking Therapeutics made up 0.02% of Point72 Asset Management's portfolio in Q2 2026, its #935 holding.
  • Point72 Asset Management first reported a position in Viking Therapeutics in Q4 2022 and has held it in 7 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.